对于语言障碍患者,Neuralink将于2025年10月启动FDA批准的试验,使用脑植入物将思想转化为文字. Neuralink to launch FDA-approved trial in October 2025, using brain implants to translate thoughts into text for people with speech impairments.

Neuralink计划从2025年10月开始进行临床试验, 帮助有言语障碍的人通过脑植入将思想转换成文字来沟通。 Neuralink plans a clinical trial starting October 2025 to help people with speech impairments communicate by translating thoughts into text using its brain implant. 经林业发展局批准的试验将解码大脑言语皮层的信号,目的是在没有外部设备的情况下恢复通讯。 The FDA-approved trial will decode signals from the brain’s speech cortex, aiming to restore communication without external devices. 虽然该技术侧重于神经病患者的医疗用途,但后来可以扩大到非医疗用途。 While focused on medical use for those with neurological conditions, the technology could later expand to nonmedical applications. 该试验标志着脑机接口开发取得了进展，尽管在公司的商业目标中对隐私、道德和长期安全的担忧仍然存在。 The trial marks progress in brain-computer interface development, though concerns about privacy, ethics, and long-term safety persist amid the company’s commercial goals.